Candesartan as a tentative treatment for COVID-19: A prospective non-randomized open-label study.

ABSTRACT:

Background

This study aimed to investigate whether the addition of candesartan to the standard care regimen improved the outcome in patients with coronavirus 2019 (COVID-19).

Methods

A prospective non-randomized open-label study was undertaken from May to August 2020 on 75 subjects (aged 18-70 years) hospitalized in Siloam Kelapa Dua Hospital. Uni- and multi-variable Cox regression analyses were performed to obtain hazard ratios (HRs). The primary outcomes were: (1) length of hospital stay; (2) time to negative swab; and (3) radiological outcome (time to improvement on chest X ray).

Results

None of the 75 patients with COVID-19 required intensive care. All patients were angiotensin-receptor-blocker naïve. In comparison with the control group, the candesartan group had

SUBMITTER: Lukito AA 

PROVIDER: S-EPMC8142270 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature